Clinicians Laura Huppert, Kelsey Natsuhara, and Magdelena Ford discuss the evidence, challenges, and real-world considerations guiding CDK4/6 inhibitor management in the adjuvant setting. Medscape Oncology

Read the full article on medscape.com